期刊文献+

Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma? 被引量:14

Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?
下载PDF
导出
摘要 AIM: To evaluate mutant p53 gene in primary hepatocellular carcinoma and to investigate the correlation between it and the recurrence of hepatocellular carcinoma.METHODS: Mutations of p53 gene were examined using antihuman p53 monoclonal antibody and immunohistochemical staining in 79 resected hepatocellular carcinomas. The correlations among variables of p53 positivity and invasiveness, disease free interval and survival were studied.In addition, in those who developed recurrence, the correlation among p53 positivity, clinical features and postrecurrence survival were also studied.RESULTS: Of these 79 cases, 64 (81%) had p53 mutation.Those patients with mutant p53 positivityhad significantly more tumor recurrence (76.6 % vs 40.0 %, P=0.0107).However, the COX proportional hazards model showed that p53 overexpression had only weak correlations with recurrence free interval and survival time (P=0.088 and 0.081), which was probably related to the short duration of follow-up. The invasiveness variables may be predictors of HCC recurrence. On univariate analysis, more patients with mutant p53 positivity had vascular permeation [78.1vs 40.0 %, P=0.0088, O.R. (odds ratio) =5.3], grade Ⅱ-ⅣV differentiation (98.4 vs 80.0 %, P=0.0203, O.R. =15.7), no complete capsule (82.8 vs 53.3 %, P=0.0346, O.R. =4.2)and daughter nodules (60.9 vs. 33.3 %, P=0.0527, O.R.=3.1) than patients with negative p53 staining. Onmultivariate analysis, only vascular permeation and grade of differentiation remained significant (P=0.042 and 0.012).There was no statistically significant correlation betweenthe status of p53 in the primary lesion and the clinical features of recurrent hepatocellular carcinomas examined,including extrahepatic metastasis (P=0.1103) and the number of recurrent tumors (P= 1.000) except for diseaseover more than one segment in the extent of recurrent tumors (P=0.0043). The post-recurrence median survival was lower in patients in whom p53 mutation had been detected in the primary lesion with a weak significance (3.42 months vs 11.0 months, P=0.051). CONCLUSION: Our findings suggest that p53 mutation correlates significantly with invasiveness including vascular permeation, grade of cellular differentiation, incomplete capsule and multinodular lesions. Hepatocellular carcinomas with p53 mutations had more tumor recurrence and p53mutation may also influence disease recurrence interval and survival time. Hepatocellular carcinomas with p53 mutations recur more extensively with a shorter survival. Therefore,p53 mutation in the primary lesion is useful as an indicator of the biological behavior of recurrent hepatocellular carcinomas. AIM:To evaluate mutant p53 gene in primary hepatocellular carcinoma and to investigate the correlation between it and the recurrence of hepatocellular carcinoma. METHODS:Mutations of p53 gene were examined using anti- human p53 monoclonal antibody and immunohistochemical staining in 79 resected hepatocellular carcinomas.The correlations among variables of p53 positivity and invasiveness,disease free interval and survival were studied. In addition,in those who developed recurrence,the correlation among p53 positivity,clinical features and post- recurrence survival were also studied. RESULTS:Of these 79 cases,64 (81%) had p53 mutation. Those patients with mutant p53 positivity had significantly more tumor recurrence (76.6 % vs 40.0 %,P=-0.0107). However,the COX proportional hazards model showed that p53 overexpression had only weak correlations with recurrence free interval and survival time (P=-0.088 and 0.081),which was probably related to the short duration of follow-up.The invasiveness variables may be predictors of HCC recurrence.On univariate analysis,more patients with mutant p53 positivity had vascular permeation [78.1 vs 40.0 %,P=-0.0088,O.R.(odds ratio)=5.3],grade Ⅱ-Ⅳ differentiation (98.4 vs 80.0 %,P=0.0203,O.R.=15.7),no complete capsule (82.8 vs 53.3 %,P=-0.0346,O.R.=4.2) and daughter nodules (60.9 vs.33.3 %,P=0.0527,O.R. =3.1) than patients with negative p53 staining.On multivariate analysis,only vascular permeation and grade of differentiation remained significant (P=-0.042 and 0.012). There was no statistically significant correlation between the status of p53 in the primary lesion and the clinical features of recurrent hepatocellular carcinomas examined, including extrahepatic metastasis (P=-0.1103) and the number of recurrent tumors (P=1.000) except for disease over more than one segment in the extent of recurrent tumors (P=0.0043).The post-recurrence median survival was lower in patients in whom p53 mutation had been detected in the primary lesion with a weak significance (3.42 months vs 11.0 months,P=-0.051). CONCLUSION:Our findings suggest that p53 mutation correlates significantly with invasiveness including vascular permeation,grade of cellular differentiation,incomplete capsule and multinodular lesions.Hepatocellular carcinomas with p53 mutations had more tumor recurrence and p53 mutation may also influence disease recurrence interval and survival time.Hepatocellular carcinomas with p53 mutations recur more extensively with a shorter survival.Therefore, p53 mutation in the primary lesion is useful as an indicator of the biological behavior of recurrent hepatocellular carcinomas.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2003年第6期1202-1207,共6页 世界胃肠病学杂志(英文版)
基金 grants from the Department of Health National Science Council,Executive Yuan,Taiwan.No.NSC 84-2331-B-195-002
  • 相关文献

参考文献52

  • 1Collier JD, Carpenter M, Butt AD, Bassendine MF. Expression of mutant p53 protein in hepatocellular carcinoma. Gut 1994; 35:98-100.
  • 2Livni N, Eid A, Ilan Y, Rivkind A, Rosenmann E, Blendis LM,Shouval D, Galun E. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 1995; 75: 2420-2426.
  • 3Saegusa M, Takano Y, Kishimoto H, Wakabayashi G, Nohga K,Okudaira M. Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas- an enhanced immunohistochemical approach. J Cancer Res Clin Oncol 1993; 119:737-744.
  • 4D'Errico A, Grigioni WF, Fiorentino M, Baccarini P, Grazi GL,Mancini AM. Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immunohistochemical study on 109 Italian patients. Pathol Int 1994; 44:682-687.
  • 5Ng IOL, Srivastava G, Chung LP, Tsang SW, Ng MM.Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people.Cancer 1994, 74:30-37.
  • 6Cohen C, DeRose PB. Immunohistochemical p53 in hepatocellular carcinoma and liver cell dysplasia. Mod Pathol 1994; 7: 536-539.
  • 7Zhao M, Zhang NX, Laissue JA, Zimmermann A. Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia and in hepatocellular carcinoma. Virchows Arch 1994;424:613-621.
  • 8Hollstein MC, Wild CP, Bleicher F, Chutimataewin S, Harris CC,Srivatanakul P, Montesano R. p53 mutations and aflatoxin B1 exposure in hepatoceUular carcinoma patients from Thailand.Int J Cancer 1993; 53:51-55.
  • 9Vesey DA, Hayward NK, Cooksley WGE. p53 gene in hepatocellular carcinomas from Australia. Cancer Detect Prey 1994; 18:123-130.
  • 10Pierre LP, Flejou JF, Fabre M, Bedossa P, Belghiti J, Gayral F,Franco D. Overexpression of p53: a rare event in a large series of white patients with hepatocellular carcinoma. Hepatology 1992;16:1171-1175.

同被引文献95

引证文献14

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部